JP2020125323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020125323A5 JP2020125323A5 JP2020073065A JP2020073065A JP2020125323A5 JP 2020125323 A5 JP2020125323 A5 JP 2020125323A5 JP 2020073065 A JP2020073065 A JP 2020073065A JP 2020073065 A JP2020073065 A JP 2020073065A JP 2020125323 A5 JP2020125323 A5 JP 2020125323A5
- Authority
- JP
- Japan
- Prior art keywords
- viral
- coat protein
- protein
- viral coat
- protein complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000565 Capsid Proteins Proteins 0.000 claims 44
- 108010067390 Viral Proteins Proteins 0.000 claims 30
- 241001465754 Metazoa Species 0.000 claims 24
- 238000000034 method Methods 0.000 claims 22
- 230000003472 neutralizing effect Effects 0.000 claims 20
- 238000004519 manufacturing process Methods 0.000 claims 16
- OQALFHMKVSJFRR-UHFFFAOYSA-N dityrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C(C=2C(=CC=C(CC(N)C(O)=O)C=2)O)=C1 OQALFHMKVSJFRR-UHFFFAOYSA-N 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 230000003612 virological effect Effects 0.000 claims 11
- 230000001681 protective effect Effects 0.000 claims 10
- 230000005875 antibody response Effects 0.000 claims 8
- 230000002163 immunogen Effects 0.000 claims 6
- 108091008875 B cell receptors Proteins 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- 241000711513 Mononegavirales Species 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 238000004132 cross linking Methods 0.000 claims 3
- 241000711573 Coronaviridae Species 0.000 claims 2
- 241000710831 Flavivirus Species 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 241000709664 Picornaviridae Species 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 101710094648 Coat protein Proteins 0.000 claims 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 102000007474 Multiprotein Complexes Human genes 0.000 claims 1
- 101710141454 Nucleoprotein Proteins 0.000 claims 1
- 101710083689 Probable capsid protein Proteins 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022128985A JP7472209B2 (ja) | 2012-05-09 | 2022-08-12 | 立体構造的に特異的なウイルス免疫原 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644830P | 2012-05-09 | 2012-05-09 | |
| US61/644,830 | 2012-05-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088600A Division JP6692853B2 (ja) | 2012-05-09 | 2018-05-02 | 立体構造的に特異的なウイルス免疫原 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022128985A Division JP7472209B2 (ja) | 2012-05-09 | 2022-08-12 | 立体構造的に特異的なウイルス免疫原 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020125323A JP2020125323A (ja) | 2020-08-20 |
| JP2020125323A5 true JP2020125323A5 (enExample) | 2021-05-20 |
Family
ID=49548782
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511675A Pending JP2015518819A (ja) | 2012-05-09 | 2013-05-09 | 立体構造的に特異的なウイルス免疫原 |
| JP2018088600A Expired - Fee Related JP6692853B2 (ja) | 2012-05-09 | 2018-05-02 | 立体構造的に特異的なウイルス免疫原 |
| JP2020073065A Pending JP2020125323A (ja) | 2012-05-09 | 2020-04-15 | 立体構造的に特異的なウイルス免疫原 |
| JP2022128985A Active JP7472209B2 (ja) | 2012-05-09 | 2022-08-12 | 立体構造的に特異的なウイルス免疫原 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511675A Pending JP2015518819A (ja) | 2012-05-09 | 2013-05-09 | 立体構造的に特異的なウイルス免疫原 |
| JP2018088600A Expired - Fee Related JP6692853B2 (ja) | 2012-05-09 | 2018-05-02 | 立体構造的に特異的なウイルス免疫原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022128985A Active JP7472209B2 (ja) | 2012-05-09 | 2022-08-12 | 立体構造的に特異的なウイルス免疫原 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US20130302366A1 (enExample) |
| EP (2) | EP3483174A1 (enExample) |
| JP (4) | JP2015518819A (enExample) |
| AU (5) | AU2013259548A1 (enExample) |
| CA (1) | CA2873048C (enExample) |
| IN (1) | IN2014DN09445A (enExample) |
| WO (1) | WO2013169961A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3024483B1 (en) | 2013-07-25 | 2020-01-15 | Calder Biosciences Inc. | Conformationally stabilized rsv pre-fusion f proteins |
| EP3027640B1 (en) | 2013-08-03 | 2018-03-07 | Avatar Medical, LLC | Influenza hemagglutinin proteins and methods of use thereof |
| AU2018313000B2 (en) | 2017-08-07 | 2025-07-03 | Calder Biosciences Inc. | Conformationally stabilized RSV pre-fusion F proteins |
| WO2019178521A1 (en) | 2018-03-16 | 2019-09-19 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for vaccination against respiratory syncitial virus infection |
| WO2021231651A2 (en) * | 2020-05-12 | 2021-11-18 | The Regents Of The University Ofcalifornia | Sars-cov2 neutralizing single domain antibody constructs |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7311920B1 (en) * | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
| JP2003511420A (ja) * | 1999-10-13 | 2003-03-25 | カイロン コーポレイション | タンパク質から細胞性免疫応答を得る方法 |
| ES2367475T3 (es) | 1999-10-15 | 2011-11-03 | Avatar Medical, L.L.C. | Proteínas estabilizadas. |
| US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
| US7179468B1 (en) * | 2000-06-08 | 2007-02-20 | Cornell Research Foundation, Inc. | Antigen for developing neutralizing antibodies to human immunodeficiency virus |
| EP1463521A4 (en) | 2001-12-17 | 2009-06-24 | Us Gov Health & Human Serv | INHIBITOR OF GP41 |
| US20080206264A1 (en) | 2003-02-04 | 2008-08-28 | New York University | Constrained Hiv V3 Loop Peptides as Novel Immunogens and Receptor Antagonists |
| US20050054572A1 (en) * | 2003-07-03 | 2005-03-10 | Marshall Christopher P. | Methods for obtaining molecules with reduced immunogenicity |
| WO2005118886A2 (en) * | 2004-06-01 | 2005-12-15 | Merck & Co., Inc. | Stable peptide mimetic of hiv gp41 fusion intermediate |
| WO2007149491A2 (en) * | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Soluble stabilized trimeric hiv env proteins and uses thereof |
| CN105566450A (zh) * | 2007-07-27 | 2016-05-11 | 伊玛提克斯生物技术有限公司 | 免疫疗法的新型免疫抗原表位 |
| BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| US20090246191A1 (en) * | 2007-10-11 | 2009-10-01 | University Of Tennessee Research Foundation | Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof |
| SMT202000101T1 (it) * | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| US20110123556A1 (en) | 2009-11-24 | 2011-05-26 | Sanjay Phogat | Immunogen prioritization for vaccine design |
| EP2572196A4 (en) | 2010-05-18 | 2014-04-23 | Christopher P Marshall | ANTIGEN IDENTIFICATION TEST THAT ACTIVATES B-CELL RECEPTORS COMPRISING NEUTRALIZING ANTIBODIES |
| US20130149336A1 (en) * | 2011-10-27 | 2013-06-13 | Brian L. Hjelle | Methods for Screening Viral Like Particles and Identifying Neutralizing Epitopes and Related Vaccines, Constructs, and Libraries |
| EP2804948B1 (en) | 2012-01-20 | 2020-04-15 | The Government of The Hong Kong Special Administrative Region of The People's Republic of China | A novel paramyxovirus and uses thereof |
-
2013
- 2013-05-08 US US13/890,226 patent/US20130302366A1/en not_active Abandoned
- 2013-05-09 JP JP2015511675A patent/JP2015518819A/ja active Pending
- 2013-05-09 WO PCT/US2013/040228 patent/WO2013169961A1/en not_active Ceased
- 2013-05-09 US US13/890,465 patent/US20130317205A1/en not_active Abandoned
- 2013-05-09 IN IN9445DEN2014 patent/IN2014DN09445A/en unknown
- 2013-05-09 CA CA2873048A patent/CA2873048C/en active Active
- 2013-05-09 EP EP18200812.8A patent/EP3483174A1/en active Pending
- 2013-05-09 EP EP13787969.8A patent/EP2846828B1/en not_active Not-in-force
- 2013-05-09 AU AU2013259548A patent/AU2013259548A1/en not_active Abandoned
-
2017
- 2017-02-03 US US15/424,107 patent/US10155023B2/en active Active
-
2018
- 2018-01-22 AU AU2018200502A patent/AU2018200502B2/en not_active Ceased
- 2018-05-02 JP JP2018088600A patent/JP6692853B2/ja not_active Expired - Fee Related
- 2018-12-08 US US16/214,074 patent/US20190105368A1/en not_active Abandoned
-
2019
- 2019-08-16 AU AU2019216695A patent/AU2019216695A1/en not_active Abandoned
-
2020
- 2020-04-15 JP JP2020073065A patent/JP2020125323A/ja active Pending
- 2020-11-30 US US17/107,067 patent/US11752191B2/en active Active
-
2021
- 2021-06-21 AU AU2021204169A patent/AU2021204169B2/en active Active
-
2022
- 2022-08-12 JP JP2022128985A patent/JP7472209B2/ja active Active
-
2023
- 2023-08-25 US US18/455,787 patent/US20240238369A1/en not_active Abandoned
-
2024
- 2024-02-22 AU AU2024201200A patent/AU2024201200A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020125323A5 (enExample) | ||
| Schirmbeck et al. | Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis | |
| Vietheer et al. | The core domain of hepatitis C virus glycoprotein E2 generates potent cross‐neutralizing antibodies in guinea pigs | |
| JPH05500517A (ja) | 後天性免疫不全症候群の予防および治療 | |
| Ulrich et al. | New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge | |
| JP2002537355A (ja) | 抗原の粘膜送達のための生体接着剤およびアジュバントの使用 | |
| WO2013185558A1 (zh) | 用于治疗hbv感染及相关疾病的多肽及抗体 | |
| Koletzki et al. | HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein | |
| US5763574A (en) | HIV-specific synthetic antigens and their use | |
| JP7146926B2 (ja) | Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン | |
| JP2015518819A5 (enExample) | ||
| TW201733616A (zh) | 包含固定化病毒粒子之疫苗 | |
| JP2022078254A5 (enExample) | ||
| Lazo et al. | A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice | |
| Deng et al. | A novel strategy for an anti-idiotype vaccine: nanobody mimicking neutralization epitope of porcine circovirus type 2 | |
| JPH0195773A (ja) | エイズの診断、予防、又は治療に有用な新規なｈｉｖ蛋白質及びペプチド類 | |
| AU2022366884A1 (en) | Engineering antigen binding to, and orientation on, adjuvants for enhanced humoral responses and immunofocusing | |
| WO2002020048A1 (en) | A classical swine fever virus epitope vaccine and its producing method | |
| CN119569835A (zh) | 呼吸道合胞病毒f蛋白及其应用 | |
| Iglesias et al. | Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV‐1 | |
| DE68926813T2 (de) | Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide | |
| CN115197969A (zh) | 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用 | |
| RU2006129097A (ru) | Новые тат-комплексы и включающие их вакцины | |
| Rajadhyaksha et al. | Immunological evaluation of three generations of anti-idiotype vaccine: study of B and T cell responses following priming with anti-idiotype, anti-idiotype peptide and its MAP structure | |
| WO2002032452A1 (en) | Composition for aids and method producing it |